Abstract: Objective To investigate the effect of levocarnitine and hemoperfusion combined with hemodialysis on cardiac function and bone metabolism in patients with uremia.Methods 60 patients with uremia admitted into our hospital from January 2015 to December 2017 were divided into two groups by draw lots,with 30 cases in each group. Control group was given hemodialysis,while research group was treated with levocarnitine and hemoperfusion based on control group. The indexes of cardiac function [left ventricular ejection fraction （LVEF）,stroke volume （SV）,fractional shortening （FS）,E/A],indexes of bone metabolism [bone alkaline phosphatase （BALP）,intact parathyroid hormone （iPTH）],indexes of renal function [blood urea nitrogen （BUN）,serum creatinine （Scr）] and adverse reactions were compared between the two groups.Results After treatment,the indexes of cardiac function （LVEF,SV,FS,E/A） in research group were higher than those in control group （P<0.05）; After treatment,the indexes of bone metabolism （BALP,iPTH） and renal function （BUN,Scr） in research group were lower than those in control group （P<0.05）; The incidence of adverse reactions in research group was 6.67%（2/30）,which was lower than 26.67%（8/30） in control group （P<0.05）.Conclusion Levocarnitine and hemoperfusion combined with hemodialysis in treatment of uremia is effective,it can improve cardiac function and renal function,reduce bone metabolism disorder,and not increase adverse reactions,which is worthy of promotion.

Key words: Levocarnitine, Hemoperfusion, Hemodialysis, Uremia, Cardiac function, Bone metabolism